As not all genes involved in pathways could exert an impact on glioma, we screened significant genes affecting the survival of glioma patients, which included TNFRSF1A (p = 5.9 e-9, R = 0.44), MALT1 (p = 9.7 e-9, R = 0.37), LY96 (p = 1 e-10, R = 0.48), NFKB2 (p = 2.5 e-8, R = 0.42), CD14 (p = 7 e-8, R = 0.41) in the NF-κB signaling pathway, SOCS3 (P = 5 e-8, R = 0.41), MAP2K3 (p = 2.4 e-9, R = 0.45), JAK3 (p = 1.7 e-5, R = 0.33), IL27RA (p = 5.9 e-8, R = 0.41), IL13RA1 (p = 3.5 e-13, R = 0.53) in the JAK/STAT signaling pathway, IL27RA (p = 5.9 e-8, R = 0.41), and IL13RA1 (p = 3.5). The gene discussed is LY96; the disease is central nervous system cancer.